Xeris Biopharma stockholders elect three Class I directors and ratify KPMG as auditor

Xeris Biopharma Holdings, Inc.

Proposal 1: All three Class I director nominees elected: Bormann (41.5M for), Kong (46.4M for), Schmid (41.5M for).
Proposal 2: Ratification of KPMG LLP as auditor for FY 2022 passed with 79.0M for, 687K against, 110K abstain.
Broker non-votes totaled 32.1M shares on director elections.
Annual meeting held June 8, 2022; 135.5M shares outstanding and entitled to vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.